Drugs / SC16.56
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04199741 | Dec 2019 → Jun 2027 expected | small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC16.56 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04199741 ↗ |
| Target | DLL3 | “the anti-DLL3 antibody SC16.56 conjugated to p-SCN-Bn-deferoxamine [DFO] serving as a chelator for zirconium-89” PMID 38950555 ↗ Jun 2024 |